Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value
$1.98−0.18 (-8.33%)
Close on Nov 12, 2026Market cap $24.73MP/E –Yield –
Aligos Therapeutics cash
Cash and short-term investments held at the end of each period.
Aligos Therapeutics's cash was $31.09M at Sep 30, 2026. For fiscal 2025 it was $77.80M, up 36.7% from the year before. The highest annual figure on record is $244.07M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.80M | +36.7% |
| FY2024 | Dec 31, 2024 | $56.90M | -58.1% |
| FY2023 | Dec 31, 2023 | $135.70M | +7.9% |
| FY2022 | Dec 31, 2022 | $125.80M | -38.9% |
| FY2021 | Dec 31, 2021 | $205.80M | -15.7% |
| FY2020 | Dec 31, 2020 | $244.07M | +106.5% |
| FY2019 | Dec 31, 2019 | $118.20M | +381.5% |
| FY2018 | Dec 31, 2018 | $24.55M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $31.09M | -68.6% |
| Q2 FY2026 | Jun 30, 2026 | $30.38M | -75.3% |
| Q1 FY2026 | Mar 31, 2026 | $54.90M | -60.2% |
| Q4 FY2025 | Dec 31, 2025 | $77.80M | +36.7% |
| Q3 FY2025 | Sep 30, 2025 | $99.10M | +32.3% |
| Q2 FY2025 | Jun 30, 2025 | $122.90M | +30.1% |
| Q1 FY2025 | Mar 31, 2025 | $137.90M | +22.4% |
| Q4 FY2024 | Dec 31, 2024 | $56.90M | -58.1% |
| Q3 FY2024 | Sep 30, 2024 | $74.90M | +6.4% |
| Q2 FY2024 | Jun 30, 2024 | $94.50M | +4.1% |
| Q1 FY2024 | Mar 31, 2024 | $112.70M | +8.9% |
| Q4 FY2023 | Dec 31, 2023 | $135.70M | +7.9% |
| Q3 FY2023 | Sep 30, 2023 | $70.40M | -50.5% |
| Q2 FY2023 | Jun 30, 2023 | $90.80M | -43.0% |
| Q1 FY2023 | Mar 31, 2023 | $103.50M | -43.5% |
| Q4 FY2022 | Dec 31, 2022 | $125.80M | -38.9% |
| Q3 FY2022 | Sep 30, 2022 | $142.30M | -41.4% |
| Q2 FY2022 | Jun 30, 2022 | $159.30M | -16.5% |
| Q1 FY2022 | Mar 31, 2022 | $183.20M | -14.2% |
| Q4 FY2021 | Dec 31, 2021 | $205.80M | -15.7% |
| Q3 FY2021 | Sep 30, 2021 | $242.70M | +662.8% |
| Q2 FY2021 | Jun 30, 2021 | $190.70M | +740.9% |
| Q1 FY2021 | Mar 31, 2021 | $213.40M | +739.7% |
| Q4 FY2020 | Dec 31, 2020 | $244.07M | +106.5% |
| Q3 FY2020 | Sep 30, 2020 | $31.82M | +50.6% |
| Q2 FY2020 | Jun 30, 2020 | $22.68M | -7.6% |
| Q1 FY2020 | Mar 31, 2020 | $25.42M | – |
| Q4 FY2019 | Dec 31, 2019 | $118.20M | – |
| Q3 FY2019 | Sep 30, 2019 | $21.13M | – |
| Q4 FY2018 | Dec 31, 2018 | $24.55M | – |
See a number that looks wrong?